Jakafi
My Prescription
Payment
Select pharmacy
$18,780.08
Print or send this coupon to your phone
AlbertsonsPowered byAbout Jakafi
Drug Details
Ruxolitinib, marketed as Jakafi, is a medication used to treat specific blood disorders and conditions, including myelofibrosis (MF) and polycythemia vera (PV) in adults, as well as graft-versus-host disease (GVHD) in individuals aged 12 and older. As a JAK inhibitor, Ruxolitinib functions by blocking JAK proteins, which are involved in cell growth and immune system responses. Although it is not a cure, Ruxolitinib helps alleviate symptoms such as abdominal discomfort, rib pain, early satiety, night sweats, itching, and bone or muscle pain associated with these disorders. It is particularly used for patients who cannot tolerate or have previously tried other medications like hydroxyurea for PV or corticosteroids for GVHD. Administered orally twice daily, common side effects may include low blood cell counts, infections, and fatigue. Always consult with a healthcare provider for advice tailored to your medical needs before starting this treatment.
Price history for Jakafi
60 Tablets, 5MG
Average retail price for Jakafi
Average SaveHealth price for Jakafi
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Jakafi dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 5MG | 60 Tablets | $18,780.08 | $313.00 |
| 10MG | 60 Tablets | $18,780.08 | $313.00 |
| 15MG | 60 Tablets | $18,780.08 | $313.00 |
| 20MG | 60 Tablets | $18,780.08 | $313.00 |
| 25MG | 60 Tablets | $18,780.08 | $313.00 |
Jakafi FAQs
Jakafi is a medication used to treat certain types of bone marrow disorders, such as myelofibrosis and polycythemia vera. It works by inhibiting specific enzymes known as Janus kinases (JAKs), which are involved in the signaling pathways that regulate blood cell production and immune function. By targeting these enzymes, Jakafi helps to reduce symptoms and control the overproduction of blood cells associated with these conditions.
Jakafi (ruxolitinib) is not considered traditional chemotherapy. It is classified as a targeted therapy, specifically a Janus kinase (JAK) inhibitor, used to treat certain types of blood disorders.
The life expectancy of patients taking Jakafi (ruxolitinib) can vary significantly depending on the underlying condition being treated, the stage of the disease, and individual patient factors. Jakafi is commonly used to treat conditions like myelofibrosis and polycythemia vera, which can have different prognoses. While Jakafi can help manage symptoms and improve quality of life, it is not a cure. Patients should discuss their specific prognosis and treatment outcomes with their healthcare provider, who can provide information tailored to their individual health status.
Jakafi is expensive due to several factors, including the costs associated with its research and development, clinical trials, and regulatory approval processes. Additionally, it is a specialized medication used to treat rare conditions, which often results in higher pricing due to limited patient populations. The costs of manufacturing, marketing, and distribution also contribute to its price. Furthermore, the pricing strategy may reflect the value it provides in terms of efficacy and the lack of alternative treatments for the conditions it addresses.
While taking Jakafi (ruxolitinib), it is advisable to avoid consuming grapefruit and grapefruit juice. Grapefruit can interfere with the metabolism of the medication, potentially leading to increased levels in the blood and a higher risk of side effects. It is always best to consult with a healthcare provider for personalized dietary recommendations while on this medication.